Clinical follow‐up in endovascular treatment for TASC C‐D lesions in femoro‐popliteal segment

Abstract

The majority of claudicating patients with femoropopliteal TASC II C and D lesions will benefit from the endovascular treatment. Patient presenting CLI have a worse outcome, nevertheless the endovascular treatment can delay amputation, preserving the native vessel and does not impede surgical bypass if needed. For this reason, we consider that endovascular treatment may be the first choice treatment even in femoropopliteal TASC II C and D lesions.

Covered stents for endovascular repair of iatrogenic injuries of iliac and femoral arteries

“…However, patients with PAD presented with more TLR events at 12 months as compared with patients without pre-existing PAD. Previous investigations of self-expandable [24][25][26][27][28][29][30] and balloon expandable stents [28,31] showed encouraging mid-term patency [28,32] with some concerns about long-term durability, especially in patients with extensive PAD [33]. These findings are broadly consistent with the results of the present study.…”

Clinical outcomes of endovascular treatment of TASC-II C and D femoropopliteal lesions with the Viabahn endoprosthesis

“…However, a larger study looking at TASC-II C and D lesions treated with a similar strategy of PTA with Viabahn stenting only in selected cases (13.7% of patients) yielded outcomes fairly similar to those seen in our study, with a primary patency rate at 1 year of 81.5% and a secondary patency rate of 85.4%. 16 Outcomes using a planned stenting strategy with ePTFE endoprostheses in femoropopliteal disease have also been reported by several authors. The randomized…”

SCAI expert consensus statement for femoral‐popliteal arterial intervention appropriate use

“…Initially, less-complex lesions (TASC A and B lesions) were felt to be amenable to endovascular therapy, whereas more complex disease lesions (TASC C and D lesions) were considered better suited for surgical revascularization. Since the publication of the TASC II document, endovascular techniques and outcomes have advanced to the extent that the vast majority of complex lesions, including TASC C and D lesions, may be treated successfully using endovascular techniques [5]. Therefore, the optimal revascularization strategy has largely removed anatomic barriers to the use of endovascular therapy in the FP segment.…”